Kadmon Announces Updated Results of KD025 in cGVHD at EHA Congress

The updated study results include four additional months of patient follow-up, through May 2, 2018. The Overall Response Rate (ORR) continues to be 65% (11/17) in Cohort 1 (KD025 200 mg QD; n=17) and 69% (11/16) in Cohort 2 (KD025 200 mg BID; n=16). Responses have been durable, with 47% (8/17) of patients in Cohort 1 having sustained a response for at least 20 weeks, up from 41% (7/17) in the last reported analysis. Initial durability data from Cohort 2 demonstrated that 38% (6/16) of patients have sustained a response for at least 20 weeks, which is comparable to durability data observed in Cohort 1 at the same median treatment duration. Durability data continue to mature across Cohorts 1 and 2. Sixty-six percent (66%; 22/33) of all patients were able to reduce doses of corticosteroids and 15% (5/33) have completely discontinued steroid use. In addition, 55% (18/33) of patients across Cohorts 1 and 2 saw a clinically meaningful improvement in cGVHD symptoms, as measured by at least a 7-point decrease in the Lee Symptom Scale score. KD025 continued to be well tolerated, with no treatment-related serious adverse events and no apparent increased risk of infection.

“KD025 continues to achieve robust and durable responses across multiple organs affected by cGVHD, while simultaneously allowing the majority of patients to taper doses of steroids,” said Amandeep Salhotra, M.D., Assistant Professor, Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, and study investigator. “In addition, the favorable tolerability profile of KD025 has allowed patients to continue on treatment and maintain responses, highlighting its potential for long-term use as a backbone of cGVHD therapy.”

Kadmon plans to initiate an open-label, pivotal study of KD025 in cGVHD in Q3 2018, based on FDA guidance received in a Type C meeting. The planned pivotal study (KD025-213) will enroll adults who have received at least two prior lines of systemic therapy for cGVHD. Patients will be randomized to receive KD025 200 mg QD or 200 mg BID (63 patients per cohort), and either dose may be considered by the FDA for the registrational dose. The primary endpoint is ORR, supported by a key secondary endpoint of Duration of Response.

“These study results continue to show accumulation of clinical benefit and underscore the significant potential of KD025 in cGVHD, particularly in patients with multiple organs involved,” said Harlan W. Waksal, M.D., President and CEO at Kadmon. “We have a clear regulatory path forward for KD025 and we look forward to initiating our pivotal study in the third quarter of this year.”

About KD025-208

KD025-208 is an ongoing Phase 2 clinical trial of KD025, Kadmon’s Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, in adults with steroid-dependent or steroid-refractory cGVHD and active disease. The dose-finding trial includes 48 patients divided into three cohorts at different dose levels (KD025 200 mg QD, 200 mg BID and 400 mg QD), enrolled sequentially following a safety assessment of each cohort. In October 2017, KD025 received orphan drug designation from the U.S. Food and Drug Administration for cGVHD.

About cGVHD

cGVHD is a potentially life-threatening condition following hematopoietic stem cell transplantation. With cGVHD, transplanted immune cells (graft) attack the patient’s cells (host), leading to inflammation and fibrosis in multiple tissues, including skin, mouth, eye, joints, liver, lung, esophagus and GI tract.

About Kadmon Holdings, Inc.

Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company developing innovative products for significant unmet medical needs. Our product pipeline is focused on inflammatory and fibrotic diseases.

Forward Looking Statements

This press release contains forward-looking statements. Such statements may be preceded by the words “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors include, but are not limited to, (i) the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; (ii) our ability to advance product candidates into, and successfully complete, clinical trials; (iii) our reliance on the success of our product candidates; (iv) the timing or likelihood of regulatory filings and approvals; (v) our ability to expand our sales and marketing capabilities; (vi) the commercialization of our product candidates, if approved; (vii) the pricing and reimbursement of our product candidates, if approved; (viii) the implementation of our business model, strategic plans for our business, product candidates and technology; (ix) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (x) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xi) costs associated with defending intellectual property infringement, product liability and other claims; (xii) regulatory developments in the United States, Europe and other jurisdictions; (xiii) estimates of our expenses, future revenues, capital requirements and our needs for additional financing; (xiv) the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; (xv) our ability to maintain and establish collaborations or obtain additional grant funding; (xvi) the rate and degree of market acceptance of our product candidates; (xvii) developments relating to our competitors and our industry, including competing therapies; (xviii) our ability to effectively manage our anticipated growth; (xix) our ability to attract and retain qualified employees and key personnel; (xx) our ability to achieve cost savings and other benefits from our efforts to streamline our operations and to not harm our business with such efforts; (xxi) the use of proceeds from our recent public offerings; (xxii) the potential benefits of any of our product candidates being granted orphan drug designation; (xxiii) the future trading price of the shares of our common stock and impact of securities analysts’ reports on these prices; and/or (xxiv) other risks and uncertainties. More detailed information about Kadmon and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the Company’s Quarterly Report on Form 10-Q filed pursuant to Section 13 of the Securities Exchange Act of 1934, as amended, with the SEC on May 8, 2018. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005079/en/